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After antigen exposure in the presence of ap-
propriate signals, naive CD8+ T lymphocytes 
undergo clonal proliferation and gain the abil-
ity to traffic to peripheral sites while they can 
differentiate into effector CTL able to lyse target 
cells and actively secrete IFN-. CD8+ T lym-
phocytes can also differentiate into long-lived 
memory CTL. After the initial phase of expan-
sion, most activated CD8+ T lymphocytes die, 
leaving a population of memory precursors 
(Kaech and Wherry, 2007; Williams and Bevan, 
2007). Compared with effector CTL, memory 
precursors are not terminally differentiated (Joshi 
and Kaech, 2008) and may remain as resting 
memory cells or redifferentiate into cytotoxic ef-
fectors. These are critical for a rapid and potent 
response upon secondary antigen encounter 
and enhanced control of infection (Kaech and 
Wherry, 2007).
T cell memory differentiation involves mul-
tiple phenotypic and functional changes, and 
a growing body of evidence suggests that the 
early stages of the immune response are crucial 
in determining the fate of responding CD8+ 
T lymphocytes (Obar and Lefrançois, 2010; 
Rutishauser and Kaech, 2010). Signals received 
through the TCR must be integrated with others 
from costimulatory molecules and cytokine and 
chemokine receptors, and together direct the 
outcome of the response (Kaech and Wherry, 
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Signals from the TCR that specifically contribute to effector versus memory CD8+ T cell 
differentiation are poorly understood. Using mice and adoptively transferred T lymphocytes 
lacking the small GTPase N-ras, we found that N-ras–deficient CD8+ T cells differentiate 
efficiently into antiviral primary effectors but have a severe defect in generating protective 
memory cells. This defect was rescued, although only partly, by rapamycin-mediated inhibi-
tion of mammalian target of rapamycin (mTOR) in vivo. The memory defect correlated with 
a marked impairment in vitro and in vivo of the antigen-mediated early induction of T-box 
transcription factor Eomesodermin (Eomes), whereas T-bet was unaffected. Besides N-ras, 
early Eomes induction in vitro required phosphoinositide 3-kinase (PI3K)–AKT but not 
extracellular signal-regulated kinase (ERK) activation, and it was largely insensitive to 
rapamycin. Consistent with N-ras coupling Eomes to T cell memory, retrovirally enforced 
expression of Eomes in N-ras–deficient CD8+ T cells effectively rescued their memory 
differentiation. Thus, our study identifies a critical role for N-ras as a TCR-proximal regu-
lator of Eomes for early determination of the CD8+ T cell memory fate.
© 2013 Iborra et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1. Effect of N-ras deficiency on activation and function of in vitro antigen-stimulated OT-I CD8+ T lymphocytes. (A) CD8+ T lympho-
cytes were isolated by negative selection from the spleen of CD45.1+ N-ras+/+ and N-ras/ OT-I TCR transgenic mice. They were stimulated for the indi-
cated times with CD45.1 WT splenocytes loaded with 109 M OVA peptide at an E/T ratio of 1/6, stained for CD45.1 and for intracellular pERK and pAKT, 
and analyzed by FACS (n = 2 experiments; results are expressed as mean ± SEM). (B) Alternatively, purified OT-I lymphocytes were stimulated at an E/T 
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2007; Williams and Bevan, 2007). Which and how these diverse 
signals regulate the generation of the long-lived memory 
T lymphocytes is still being defined. Particularly, little is known 
about which signals proximal or even related to the TCR 
regulate these differentiation processes (Teixeiro et al., 2009). 
Recently, the balance of expression between transcription 
factors eomesodermin (Eomes) and T-bet has been proposed 
to be critical in determining whether CD8+ T cells adopt 
memory or effector fates, with Eomes being associated to 
memory commitment (Intlekofer et al., 2005; Banerjee et al., 
2010). The mammalian target of rapamycin (mTOR) kinase 
plays a critical role in determining CD8+ T cell fate (Araki 
et al., 2009; Pearce et al., 2009) and affects Eomes and T-bet 
levels at least after IL-12 signaling (Rao et al., 2010; Li et al., 
2011), but more mechanistic information remains to be elu-
cidated. Specifically, there is little information on which early 
TCR signals regulate the expression of these transcription fac-
tors in antigen-responding CD8+ T lymphocytes and thereby 
determine T cell memory commitment.
A wide variety of extracellular stimuli activate guanine nu-
cleotide binding proteins of the Ras family which, cycling as 
a binary signal switch, control multiple cellular responses 
(Olson and Marais, 2000). The different isoforms of classical 
Ras proteins (H-ras, N-ras, and K-ras 4A and 4B) have con-
served effector binding domains but differ substantially in 
their carboxyl-terminal region, which is important for selec-
tive membrane association, compartmentalization (Mor and 
Philips, 2006), and activation (Ibiza et al., 2008). In nonlym-
phoid cell lines, N-ras has been implicated in controlling Stat1 
and apoptosis (Castellano et al., 2007). All Ras isoforms are ex-
pressed in lymphocytes and have been collectively implicated 
in signaling downstream of the TCR for T-lymphocyte devel-
opment and function by using T cell lines or transgenic mice 
expressing a dominant-negative Ras protein that inhibits all 
Ras isoforms (Scheele et al., 2007). More recently, the analysis 
of mice specifically lacking N-ras showed that this Ras isoform 
appears not to be essential for thymocyte development (Pérez 
de Castro et al., 2003; Iborra et al., 2011), although it is involved 
in CD4+ Th1 polarization and immune responses (Iborra et al., 
2011). Here, we sought to determine whether the N-ras iso-
form is necessary for mature CD8+ T lymphocyte differentia-
tion and function after a viral infection. Our results show that 
in CD8+ T lymphocytes, N-ras is a key mediator of early sig-
nals downstream of the TCR that control Eomes but not T-bet 
expression and thereby the generation of functional protective 
memory CD8+ T lymphocytes but not effector cells.
RESULTS
Impact of N-ras deficiency on OT-I TCR transgenic CD8+  
T lymphocyte activation and effector functions in vitro
Several lines of evidence suggest that N-ras is a particularly im-
portant Ras isoform in T cell lines (Perez de Castro et al., 2004), 
thymocytes, and for polarization of mature CD4+ T lym-
phocytes. To test whether N-ras is necessary for mature CD8+ 
T lymphocyte activation after antigen stimulation, we gener-
ated N-ras/ mice expressing the transgenic OT-I TCR spe-
cific for OVA peptide 257SIINFEKL264 presented by H-2Kb. 
We first assessed early TCR signaling events after antigen stim-
ulation in vitro. Similar to what has been previously shown for 
N-ras/ thymocytes (Pérez de Castro et al., 2003; Iborra et al., 
2011), N-ras deficiency barely affected extracellular signal-
regulated kinases (ERK) activation (Fig. 1 A). In contrast, phos-
phorylation of AKT at T306, a phosphoinositide 3-kinase 
(PI3K)–dependent event, was clearly deregulated in the absence 
of N-ras. Accordingly, nonstimulated N-ras/ cells exhibited 
increased basal levels of phospho-AKT compared with wild-
type counterparts (Pérez de Castro et al., 2003), and upon ex-
posure to antigen they were unable to sustain it (Fig. 1 A).
After stimulation with 1010 M OVA peptide, N-ras/ 
OT-I CD8+ T lymphocytes were comparable to WT cells in 
terms of up-regulation of activation markers (CD69, CD25, 
and CD44) and down-regulation of CD62L, but less sensitive 
to decreasing concentrations of either OVA (Fig. 1, B and C) 
or the weaker altered peptides Q4R7 and Q4H7 (Daniels 
et al., 2006), derived from the original OVA peptide (Fig. 1 C). 
Also, when stimulated with OVA peptide, N-ras/ OT-I 
CD8+ T cells exhibited IL-2 production (Fig.1 D) and prolif-
eration (Fig. 1 E) comparable to WT counterparts. Importantly, 
regardless of the abundance of antigen upon restimulation, 
both cell types displayed similar IFN- secretion (Fig. 1 F) 
and cytotoxic activity (Fig. 1 G). Thus, despite reduced sensi-
tivity to antigen and impaired early AKT activation, N-ras/ 
CD8+ T cells were capable of activation and acquisition of 
hallmark effector functions.
CD8+ T lymphocyte primary responses to viral infection  
are not impaired by N-ras deficiency in vivo
Next, we sought to determine the role of N-ras in CD8+  
T lymphocyte primary responses in vivo. We infected WT 
and N-ras/ mice with a recombinant vaccinia virus (VACV) 
expressing full length OVA protein (rVACV-OVA) and ana-
lyzed the CD8+ T lymphocyte responses to OVA and VACV 
immunodominant 20TSYKFESV27 (B8R) peptides. At the 
ratio of 1/5 with N-ras+/+ DC pulsed with titrated concentrations of OVA peptide, stained for CD69 and CD25 48 h later, or for CD44 and CD62L 72 h later, 
and gated on CD8+ cells for FACS. Results are expressed as mean ± SEM. (C) OT-I lymphocytes were stimulated for 16 h as in B with titrated concentra-
tions of OVA peptide or of the two weaker partial agonist peptides Q4R7 and Q4H7, and CD69 expression was monitored. Results are expressed as mean ± SD.  
(D) To measure intracellular IL-2 production, brefeldin A was added for 16 h after 3-h stimulation with 109 M OVA peptide. (E) To measure proliferation, 
CFSE-labeled purified lymphocytes were co-cultured with N-ras+/+ mDC prepulsed with 107 M OVA peptide at an E/T ratio of 1/5, and analyzed by FACS 
72 h later. (F) OT-I lymphocytes were stimulated as in D for 72 h, harvested, washed, and restimulated with OVA-pulsed DC. IFN- production was deter-
mined 16 h later by ICS. (G) To determine the cytotoxic activity, a 51Cr release assay was performed culturing OVA-specific CTL lines generated from WT or 
N-ras/ OT-I mice with 51Cr-labeled target cells and with titrated concentrations of OVA peptide. Specific lysis is shown as the mean of triplicate wells. 
Data shown in B–G are representative of at least three independent experiments.
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Figure 2. N-ras–deficient mice mount efficient primary CD8+ T lymphocyte effector responses after VACV infection and after DC immuni-
zation. WT and N-ras/ mice were i.p. infected with rVACV-OVA (A–E) or immunized with a mixture of mDC loaded with B8R and OVA peptides (F and G). 
On day 7 p.i., splenocytes and PBMCs were harvested and the frequency of B8R-specific T cells within the CD8+ population (A) and the number of  
B8R-specific splenic CD8+ T cells producing IFN-, as well as their geometric MFI of IFN- expression, were determined ex vivo (B; n = 4, 2 experiments; 
results are expressed as mean ± SEM). ***, P < 0.0005. (C) In vivo function of day 7 p.i. primary CD8+ T lymphocytes was assessed in in vivo killing assays 
(n = 5, two experiments). The numbers in the histograms indicate the percentage of specific lysis. Results are expressed as mean ± SEM. (D) On day 7 p.i., 
surface expression of KLRG1, IL-7R (CD127), CD62L, and IL-2R/IL-15R (CD122) in CD8+ splenocytes from naive mice or in CD8+, H-2KbB8R+ spleno-
cytes from infected mice was measured and a representative histogram per molecule is shown. The numbers within the histograms indicate the percent-
age of cells. (E) Infectious virus titer in the ovary was determined on the indicated days p.i. Dots represent titers for each individual ovary and the horizontal 
dashes represent the mean for each time point. Detection limit is indicated by the long horizontal line. (F and G) On day 7 after DC immunization, the 
number of B8R-and OVA-specific splenic CD8+ T cells producing IFN- were determined ex vivo as in B (n = 5, two experiments; F) and in vivo killing  
assays were performed as in C (n = 5, two experiments; G). **, P < 0.005. Results (F and G) are expressed as mean ± SEM.
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peak of the primary response, day 7, the frequency of antigen- 
specific CD8+ T cells in the spleen and blood was as high in 
the spleen and higher in blood in N-ras/ compared with 
WT mice when assessed by ex vivo KbB8R pentamer staining 
(Fig. 2 A) or by intracellular IFN- expression (Fig. 2 B), with 
N-ras/ cells producing amounts of IFN- on a per cell basis 
equivalent to those of WT counterparts (Fig. 2 B, far right). 
The cytotoxic activity of CD8+ T lymphocytes in vivo was 
also unaffected by the absence of N-ras, as both type of mice 
cleared peptide-bearing cells with the same efficiency (Fig. 2 C). 
Similar results were obtained for the CD8+ T cell response 
to OVA peptide (not depicted). Furthermore, up-regulation 
of KLGR1 and down-regulation of CD62L, events associated 
with acquisition of a terminal effector phenotype, were mod-
erately reduced or similar, respectively, in N-ras/ cells 
compared with WT counterparts (Fig. 2 D, left). Sustained 
expression of receptors for IL-15 and IL-7, a distinctive feature 
of putative memory precursors among antigen-responding 
cells (Williams and Bevan, 2007), was differentially affected by 
the N-ras deficiency. IL-2R/IL-15R was equally expressed 
on both cell types. On the contrary, the number of CD127+ 
cells was lower in N-ras/ mice at the peak of the primary 
Figure 3. Defective memory responses of N-ras–deficient mice upon VACV infection or DC immunization. WT and N-ras/ mice were either in-
fected with rVACV-OVA (A–C) or immunized with a mixture of mDC loaded with B8R and OVA peptides (D–F). (A and B) On day 45 after infection, splenocytes 
and PBMCs were harvested and the frequency of B8R-specific T cells within the CD8+ population (A) and the number of B8R-specific splenic CD8+ T cells pro-
ducing IFN- (B) were determined ex vivo (n = 4, two experiments). **, P < 0.005. (C) In vivo function of day 45 p.i. memory T cells was assessed in an in vivo 
killing assay (n = 6, two experiments). (D and E) On day 35 after DC immunization, the frequency of B8R- and OVA-specific T lymphocytes within the CD8+ pop-
ulation (D) and the number of B8R- and OVA-specific splenic CD8+ T cells producing IFN- (E) were determined ex vivo (n = 6, two experiments). (F) In vivo 
function of day 35 p.i. memory T cells was assessed in an in vivo killing assay (n = 6, two experiments). Results are expressed as mean ± SEM. ***, P < 0.0005.
1468 Protective CD8+ T cell memory requires N-ras | Iborra et al.
memory stage were mildly but consistently lower in infected 
(Fig. 3, A and B) or similar in DC-vaccinated N-ras/ mice 
(Fig. 3, D and E). In both settings, however, N-ras/ mice 
were clearly less efficient than WT animals in eliminating B8R-
bearing splenocytes in vivo (Fig. 3, C and F).
Next, we assessed the ability of N-ras/ CD8+ T lym-
phocytes to mount rapid and potent recall responses against 
challenge infection, a hallmark of memory lymphocytes. 
A defective secondary response was found in N-ras/ mice 
immunized with peptide-coated DCs. When vaccinated WT 
mice were challenged with virus, the number of splenic and 
peritoneal B8R- and OVA-specific CD8+ T cells was increased 
12–23-fold with respect to nonpulsed DC as controls. 
Remarkably, in N-ras/ mice, the number of CD8+ T cells 
specific for either antigen increased only two- to threefold as 
a consequence of priming (Fig. 4 A). Next, we tested the im-
pact of N-ras deficiency on the protection against VACV 
challenge infection provided by memory CD8+ T lymphocytes. 
N-ras+/+ and N-ras/ mice vaccinated with B8R-pulsed or 
response (Fig. 2 D, right), but they gradually reached the levels 
of wild-type cells in the weeks following primary infection 
(not depicted).
Both N-ras+/+ and N-ras/ mice were able to similarly con-
trol VACV infection and were thus exposed to a similar antigen 
load (Fig. 2 E). Furthermore, after immunization with B8R and 
OVA peptide-loaded DC, which selectively induce the CD8+ 
compartment while providing a less inflammatory priming en-
vironment (Badovinac et al., 2005), both types of mice also gen-
erated a fully functional primary response (Fig. 2, F and G). 
Thus, N-ras seemed to be dispensable also in vivo for acquisi-
tion of the two main functional hallmarks of effector CD8+ T 
lymphocytes, namely IFN- production and cytotoxic activity.
N-ras deficiency impairs CD8+ T lymphocyte  
memory and secondary responses
Furthermore, we studied the memory response to VACV in-
fection or DC immunization and found that the frequencies and 
numbers of B8R-specific IFN-–producing CD8+ T cells at the 
Figure 4. CD8+ T lymphocyte protective 
secondary responses are impaired in  
N-ras–deficient mice. (A) WT and N-ras/ 
mice were injected with unpulsed mDC or 
mDC pulsed with B8R and OVA peptides. On 
day 35, mice were infected i.p. with rVACV-
OVA and, 5 d later, IFN- production by B8R- 
and OVA-specific splenic and PEC CD8+  
T lymphocytes was determined ex vivo (n = 4, 
two experiments). ***, P < 0.0005. (B) Mice 
primed with B8R-pulsed mDC were chal-
lenged with VACV intradermally in both ear 
pinnae on day 35. On indicated days after 
challenge infection, lesion diameter was de-
termined with a digital caliper (n = 6 for 
unprimed mice, n = 8 for B8R-loaded mDC-
primed mice; two experiments). Results in  
A and B are expressed as mean ± SEM. Statis-
tics was performed comparing unprimed 
versus primed mice for either WT or N-ras/ 
mice. (C) Infectious virus titers in the ears and 
frequency of B8R-specific T lymphocytes 
within the CD8+ population in the draining 
retromaxillar lymph nodes (bottom dot plots) 
were determined 6 d p.i. (n = 6 for mDC-
injected mice, n = 12 for B8R-loaded mDC-
primed mice, two experiments). Horizontal 
bars show the mean values. ***, P < 0.0005.
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would also indicate that homing to the spleen is not affected 
by N-ras deficiency, as previously described for naive CD8+ 
T cells in N-ras–deficient mice and in OT-I TCR trans-
genic mice lacking N-ras (Pérez de Castro et al., 2003; Iborra 
et al., 2011).
Next, for the analysis of the secondary response, we trans-
ferred purified N-ras+/+ and N-ras/ OT-I cells into WT 
congenic recipients and immunized them with DCs pulsed 
with the OVA peptide (Fig. 5 C). As expected from Fig. 2 F, 
both types of OT-I cells exhibited a comparable primary 
response. DC priming in a noninflammatory environment 
accelerates CD8+ T lymphocyte memory differentiation 
(Badovinac et al., 2005), quickly promoting their ability to 
undergo secondary expansion upon rechallenge. In addition, 
this approach was used because DC immunization did not 
result in any differences in the number of CD8+ T lympho-
cytes homing to the spleen (at 35 d post infection [p.i.] in 
Fig. 3 E, and not depicted for earlier times after DC immuni-
zation). Therefore, 8 d later, N-ras+/+ and N-ras/ OT-I cells 
were isolated and cotransferred into new congenic recipi-
ents that were subsequently infected with rVACV-OVA. 5 d 
after challenge, we found higher frequencies as well as num-
bers of WT OT-I splenic cells than of N-ras/ OT-I cells 
(Fig. 5 C). Therefore, the N-ras deficiency clearly caused a CD8+ 
T cell–intrinsic defect in the secondary response of memory-
fated cells.
nonpulsed DCs were infected in the ear pinnae with VACV 
(Tscharke and Smith, 1999). In unprimed mice, the develop-
ment of dermal lesions and their resolution was not affected 
by N-ras deficiency (Fig. 4 B). In WT mice, vaccination with 
B8R-pulsed DCs significantly reduced dermal pathology, 
and virus titer in the infected ear was reduced 500-fold on 
day 6 (Fig. 4 C). In contrast, ear lesion development in B8R-
DC–vaccinated N-ras/ mice was closer to that of the unprimed 
controls throughout the infection, and virus titer was reduced 
only 10-fold (Fig. 4, B and C). The reduced frequency of B8R-
specific CD8+ T lymphocytes in the respective retromaxillar 
draining lymph nodes after VACV challenge (Fig. 4 C, bottom) 
correlated with the impaired protection caused by N-ras 
deficiency. Collectively, these data indicate that N-ras signal-
ing is required for the secondary response of memory CD8+ 
T lymphocytes that mediate protective immunity against a 
challenge infection.
The defects of N-ras–deficient mice in generating memory 
and a secondary response are CD8+ T cell intrinsic
For the analysis of the primary response, small numbers of 
purified N-ras+/+ and N-ras/ OT-I CD8+ T lymphocytes were 
cotransferred into the same congenic WT recipient. Upon 
primary infection, splenic N-ras/ OT-I cells expanded bet-
ter (Fig. 5 A) but were similar to WT OT-I cells in differen-
tiating into IFN-–producing cells (Fig. 5 B). These results 
Figure 5. N-ras is intrinsically required  
in CD8+ T lymphocytes for an efficient 
secondary response but not for a primary 
response. (A and B) Around 200 purified CD8+ 
T cells from CD45.1+ CD45.2+ N-ras+/+ OT-I and 
CD45.1+ CD45.2 N-ras/ OT-I TCR trans-
genic mice were cotransferred into the same 
CD45.1 CD45.2+ N-ras+/+ C57BL/6 recipients, 
which were then infected with rVACV-OVA. At 
7 d p.i., the frequency and numbers of both  
N-ras+/+ and N-ras/ OT-I cells (A) and ex vivo 
IFN- production by OVA-specific CD8+ T lym-
phocytes were determined (n = 4, two experi-
ments) (B). Results are expressed as mean ± 
SEM. **, P < 0.005. (C) Around 200 purified 
CD8+ N-ras+/+ or N-ras/ transgenic OT-I cells 
were separately transferred into N-ras+/+ re-
cipients that were then immunized with mDCs 
pulsed with OVA peptide. From each recipient, 
CD45.1+ cells were purified 8 d after priming 
and 200 cells cotransferred into the same con-
genic recipients that were then infected with 
rVACV-OVA. The frequency and numbers of 
both splenic N-ras+/+ and N-ras/ transgenic 
OT-I cells were determined 5 d after challenge 
(n = 3, 2 experiments, results are expressed as 
mean ± SEM). For comparison, naive OT-I cells 
were adoptively transferred into recipient mice 
that were subsequently infected as in A and 
euthanatized 5 d later (primary response; not 
depicted). ***, P < 0.0005.
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mTOR inhibition by rapamycin in vivo partially rescues  
the defect in memory differentiation and function  
of N-ras–deficient CD8+ T lymphocytes
A role for mTOR in regulating effector versus memory CD8+ 
T cell development has been recently unveiled with the use of 
mTORC1 inhibitor rapamycin (Araki et al., 2009; Pearce et al., 
2009). We therefore explored whether the memory-promoting 
effect of rapamycin in vivo could rescue the defect in genera-
tion of functional memory caused by the N-ras deficiency 
(Fig. 6). To this end, rapamycin-treated or untreated N-ras+/+ 
and N-ras/ OT-I cells were adoptively transferred into the 
same recipient mice, which were then immunized with anti-
gen-loaded DC in the presence or absence of rapamycin and 
later infected with virus (as depicted in Fig. 5 C). Rapamycin 
Figure 6. Inhibition of mTOR in vivo with rapamycin partially rescues the N-ras–deficient CD8+ T cell–intrinsic defects in secondary responses, 
functional memory, and antiviral protective immunity. (A and B) Following a similar protocol to that depicted in Fig. 5 A for the study of the primary 
response, N-ras+/+ or N-ras/ OT-I cells were treated or not with rapamycin and transferred into recipient mice. 1 d before rVACV-OVA infection, daily treat-
ment or no treatment of recipient mice with rapamycin was started and maintained for 6 d. For the study of the secondary response after infection, a proto-
col similar to that depicted in Fig. 5 B was used, but cells were treated or not with rapamycin. 1 d before DC immunization, daily treatment or no treatment of 
recipient mice with rapamycin was started and maintained for 8 d. The frequency and numbers of splenic N-ras+/+ and N-ras/ transgenic OT-I cells were 
determined 8 d after primary antigen exposure (not depicted) and 5 d after challenge, for which representative dot plots and the mean ± SEM data are shown 
(A). Fold effect of rapamycin treatment during the primary and secondary responses was calculated as the ratio of mean OT-I cell numbers in treated versus 
untreated animals (n = 3, two experiments; B). (C and D) WT and N-ras/ mice were infected as in Fig. 3 A and treated or not with rapamycin as above. On 
day 45 p.i., IFN- production by B8R- and OVA-specific splenic CD8+ T lymphocytes (n = 3, two experiments, results are expressed as mean ± SEM) was  
determined ex vivo (C), and the cytotoxic activity specific for B8R peptide was assessed in vivo. Fold effect of rapamycin was calculated as in B (n = 3, two 
experiments, results are expressed as mean ± SEM; D). (E and F) WT and N-ras/ mice were vaccinated with peptide-loaded mDC as in Fig. 4 A and treated  
or not with rapamycin as above. On day 35, mice were infected with rVACV-OVA, and 5 d later ex vivo IFN- production by B8R- and OVA-specific splenic 
CD8+ T lymphocytes was analyzed as a measure of functional secondary responses (n = 4, two experiments; E), whereas determination of infectious virus 
titers in the ovaries detected protective immunity (F). Horizontal bars show the mean values. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
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by rapamycin (Fig. 7 B). Furthermore, after viral challenge of 
DC-immunized mice, Eomes levels remained significantly lower 
in N-ras/ compared with WT responding memory cells 
(Fig. 7 C). Together, these results suggest that N-ras/ CD8+ 
T lymphocytes harbor a cell-intrinsic defect affecting Eomes 
but not T-bet expression during distinct stages of the in vivo 
CD8+ response.
To further test whether N-ras is involved in regulating 
T-bet and Eomes in antigen-stimulated CD8+ T lymphocytes 
at earlier times, we analyzed induction of these transcription 
factors after exposure to antigen in vitro. As shown in Fig. 7 
(D and E), the magnitude of T-bet induction was comparable 
in N-ras–sufficient and –deficient OT-I cells. In overt con-
trast, Eomes expression was consistently impaired in N-ras/ 
OT-I cells after stimulation with antigen, which correlated 
with the memory defect of N-ras/ mice.
Abundance of cognate antigen and the strength of TCR 
signals have been shown to impact effector versus memory fate 
decision (Zehn et al., 2009; Corse et al., 2011; Leignadier et al., 
2011). However, the influence of these factors in the expression 
of fate-determining transcription factors, in particular that of 
T-bet and Eomes, had not been evaluated in detail. To test this, 
naive N-ras+/+ and N-ras/ OT-I cells were stimulated with 
the strong OVA peptide agonist or with the weaker altered 
peptide ligands, Q4R7 and Q4H7. We tested concentrations 
promoting maximal (EC100) or half-maximal (EC50) CD69 
induction response for each genotype and peptide (as deter-
mined in Fig. 1 C). By 72 h (Fig. 7 E), T-bet induction was 
comparable in N-ras–sufficient and –deficient OT-I cells irre-
spective of peptide affinity or concentration. In contrast, Eomes 
expression was always induced to a lesser extent in N-ras/ 
compared with N-ras–sufficient cells. Collectively, these re-
sults confirm the strong dependence of Eomes expression on 
N-ras–mediated signaling and independently of the nature or 
abundance of the antigen.
Early induction of Eomes after TCR activation  
involves the PI3K–AKT but not the ERK pathway
In T lymphocytes, early TCR-triggered activation of Ras re-
sults in downstream coupling to the ERK and PI3K pathways. 
To test the involvement of these pathways in the regulation 
of Eomes expression by the N-ras isoform, naive N-ras+/+ OT-I 
cells were stimulated with antigen in the presence or absence 
of PD98059, an inhibitor of MEK-1, an upstream activator 
of ERK kinases, or of wortmannin, a general PI3K inhibitor 
(Fig. 8 A). Inhibition of ERK activation had no major effect on 
Eomes induction, consistent with the lack of effect of N-ras 
deficiency on ERK activation (Fig. 1 A).
In contrast, PI3K inhibition by wortmannin strongly 
suppressed antigen-mediated Eomes induction, mimicking 
the effect of the N-ras deficiency (Fig. 8 A). Together with 
data showing a deregulated antigen-induced AKT activity in 
N-ras/ cells (Fig. 1 A), these results suggest that N-ras acts 
as a critical inducer of early Eomes expression via the PI3K–
AKT pathway. To gain further insight, we analyzed the effect 
of specific PI3K and AKT pharmacological inhibitors on Eomes 
treatment consistently ameliorated the secondary expansion of 
antigen-specific N-ras/ cells, although only partly compared 
with WT counterparts treated with the inhibitor (Fig. 6 A). 
Nonetheless, while there was no differential effect from rapa-
mycin on the antigen-driven primary expansion of OT-I CD8+ 
T cells of either genotype, rapamycin-treated N-ras/ cells ex-
panded 2.5-fold more than wild-type cells after secondary 
antigen challenge (Fig. 6 B).
Next, we determined the effects of rapamycin treatment 
in vivo on the memory response to rVACV-OVA infection. 
The numbers of B8R-specific and OVA-specific IFN-– 
producing CD8+ T cells were significantly increased in rapa-
mycin-treated compared with untreated N-ras/ mice, but 
to a lesser extent than in rapamycin-treated WT counter-
parts (Fig. 6 C). Similar results were obtained when the in vivo 
cytotoxic activity of memory cells was analyzed. Again, rapa-
mycin ameliorated the capacity of N-ras/ mice to eliminate 
antigen-bearing splenocytes in vivo (Fig. 6 D, left). Of note, 
the proportional improvement by rapamycin of the memory 
cytotoxic response was superior in N-ras/ than in WT 
mice (Fig. 6 D, right).
We also tested the impact of rapamycin treatment on the 
recall response in DC-immunized mice. Also in this respect, 
rapamycin enhanced the expansion of responding memory 
CD8+ T cells (Fig. 6 E) and protective memory (Fig. 6 F) in 
N-ras/ mice, but only partly in comparison with WT mice.
In all settings where CD8+ memory was assessed, the en-
hancing effects of rapamycin were more prominent in N-ras/ 
than in WT mice or cells, but rapamycin-treated WT cells 
showed higher responses than their treated N-ras/ counter-
parts. This supports the notion that the N-ras deficiency could 
affect other key events involved in memory differentiation that 
are not negatively regulated by mTOR.
N-ras deficiency caused an impairment of the  
antigen-mediated induction of T-box transcription  
factor Eomes, but not of T-bet
It has been proposed that the balance in the expression of tran-
scription factors T-bet and Eomes impacts the effector versus 
memory T cell commitment (Intlekofer et al., 2005; Banerjee 
et al., 2010). To test the role of N-ras in the control of Eomes 
expression in differentiating CD8+ T lymphocytes in vivo, and 
the effect of inhibiting mTOR by rapamycin, naive N-ras+/+ 
and N-ras/ OT-I cells, untreated or treated with rapamycin, 
were adoptively cotransferred into WT mice. Recipient mice 
were untreated or treated with the inhibitor and infected with 
rVACV-OVA. OT-I T cells were analyzed 7 d later ex vivo for 
expression of T-bet and Eomes (Fig. 7 A). T-bet expression 
was comparable in cells of both genotypes and mostly un-
affected by rapamycin. In contrast, Eomes expression was sig-
nificantly lower in N-ras/ OT-I cells, and partly rescued by 
rapamycin treatment, as the rapamycin effect was superior in 
WT OT-I cells (Fig. 7 A). Similarly, KbB8R+ CD8+ T lympho-
cytes induced in N-ras/ mice by VACV infection showed a 
consistently lower level of Eomes expression than their WT 
counterparts after primary infection, which was also rescued 
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Figure 7. N-ras–deficient CD8+ T lymphocytes have an intrinsic deficiency in intracellular expression of Eomes transcription factor during 
the primary and secondary antiviral responses in vivo and in vitro. (A) Around 200 N-ras+/+ or N-ras/ OT-I cells, either treated or not with rapa-
mycin, were cotransferred as in Figs. 5 (A and B) and 6 (A and B) into the same N-ras+/+ recipients, which were then infected with rVACV-OVA and treated 
or not with rapamycin as in Fig. 6 (A and B) for 8 d. CD45.1+ OT-I cells were stained for intracellular T-bet and Eomes expression at 7 d p.i. and discrimi-
nated as WT or N-ras/ according to CD45.2 expression (n = 3, two experiments). The graphs below represent mean ± SEM. (B) To study the primary 
response, WT and N-ras/ mice were infected as in Fig. 2 A and treated or not with rapamycin as before. On day 7 p.i., Eomes expression was determined 
by FACS in CD8+ T lymphocytes and analyzed with respect to their staining with MHC H-2KbB8R pentamer (n = 3, two experiments). (C) For measuring the 
secondary response, WT and N-ras/ mice were vaccinated with peptide-pulsed mDC and then infected as in Figs. 4 A and 6 (E and F). On day 5 p.i., 
Eomes expression and staining with H-2KbB8R pentamer was determined by FACS in CD8+ T lymphocytes (n = 3). The graphs below in B and C represent 
mean ± SEM Eomes expression in H-2KbB8R pentamer-positive CD8+ T lymphocytes. (D and E) Purified CD45.1+ N-ras+/+ and N-ras/ OT-I CD8+ T lym-
phocytes were stimulated in vitro for 72 h at an E/T ratio of 1/6 with CD45.1 N-ras+/+ splenocytes loaded or not with nonlimiting OVA peptide concentration 
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induction after antigen exposure (Fig. 8 B). Inhibition of PI3K 
or AKT resulted in a marked decrease in Eomes induction, 
which was comparable to the effect of LY294002, a general 
PI3K inhibitor. Furthermore, interfering PI3K activity affected 
Eomes induction but only at the highest dose of inhibitor 
tested, and to a lesser extent than did PI3K and AKT in-
hibitors, whereas PI3K inhibition and ERK inhibition by 
UO126 had no significant effect. Together, these results suggest 
that PI3K, most likely via AKT, but not the ERK pathway, 
is involved in regulating early Eomes expression in antigen-
activated CD8+ T cells.
Impairment of the antigen-mediated induction of Eomes  
by N-ras deficiency was independent of mTOR at early priming 
times but partly rescued by mTOR inhibition at late times
It has been suggested that mTOR activity regulates the balance 
between T-bet and Eomes expression in CD8+ T cells in re-
sponse to antigen plus IL-12 (Rao et al., 2010). Moreover, the 
Ras pathway has recently been involved in TCR-induced 
mTOR activation (Gorentla et al., 2011), although the rele-
vant Ras isoform was not identified. These findings prompted 
us to carefully analyze the kinetics and magnitude of T-bet and 
Eomes induction, and the effect of rapamycin, in N-ras–
sufficient and –deficient CD8+ T cells at early and late times 
after antigen exposure in vitro (Fig. 9).
Rapamycin had no effect on T-bet expression in WT or 
N-ras/ OT-I cells stimulated only with antigen (Fig. 9 A) and, 
as previously shown for WT cells (Rao et al., 2010), reverted 
the IL-12–induced enhancement of T-bet expression in both 
cases (Fig. 9 B). In addition, in WT OT-I cells, rapamycin treat-
ment had no effect on Eomes expression except at 72 h after 
antigen exposure (Fig. 9 A), suggesting that early Eomes induc-
tion occurs in an mTOR-independent manner. Only when 
Eomes expression was poorly or not induced in N-ras/ OT-I 
cells (Fig. 9 A) or in either cell genotype stimulated in the pres-
ence of IL-12 (Fig. 9 B) did inhibition of mTOR consistently 
ameliorate Eomes expression at late time points (48–72 h). 
Thus, early control of Eomes induction in antigen-responding 
CD8+ T lymphocytes required N-ras and seemed to involve sig-
naling pathways other than mTOR. These results correlate with 
the partial rescue of low Eomes expressing N-ras/ CD8+  
T cells by rapamycin in vivo. However, later during CD8+  
T cell priming, N-ras and mTOR seem to converge at the level 
of Eomes to regulate its expression in an opposite manner.
Forced expression of Eomes rescues the CD8+ T cell–intrinsic 
defect in memory caused by the N-ras deficiency
To test whether the defect in Eomes induction of N-ras/ 
CD8+ T cells was associated with their intrinsic defect in gen-
erating functional memory cells, expression of Eomes was forced 
in N-ras/ T lymphocytes. To this end, wild-type or N-ras/ 
OT-I cells were activated with OVA peptide through the TCR, 
transduced with a retrovirus expressing Eomes and GFP, and 
adoptively transferred into recipient mice that were then in-
fected with rVACV-OVA. As shown in Fig. 10, during the 
primary response transduced GFP+ and transferred CD45.1+ 
(109 M; D), or with OVA and the weak agonists Q4R7 and Q4H7 peptides at concentrations that induced either the maximal (EC100) or half-maximal 
(EC50) CD69 expression (as determined in Fig. 1 C; E). Cultures were then stained for CD45.1 and CD25 for gating and for transcription factors T-bet and 
Eomes and analyzed by FACS (three experiments). Results in E are expressed as mean ± SEM. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
 
Figure 8. Involvement of PI3K and AKT 
but not of ERK in the induction of Eomes 
after antigen stimulation. Purified N-ras+/+ 
OT-I CD8+ T cells were pretreated or not with 
the indicated inhibitors for ERK kinase 
(PD98059) and PI3K (wortmannin), stimu-
lated with 109 M OVA peptide as in Fig. 7 D, 
and incubated in the presence of the inhibi-
tors for the indicated times (A), or similarly 
stimulated and treated with the inhibitors for 
ERK kinase (UO126), PI3K (LY294002), PI3K 
(inhibitor VII) PI3K (VI), PI3K, or AKT (VIII) 
at graded concentrations, and stained for 
Eomes after 48 h (B). Concentrations in B are 
indicated in Materials and methods and the 
highest to lowest depicted in black to gray to 
white bars, respectively. Statistical signifi-
cance is indicated for untreated versus wort-
mannin treated cells in A (three experiments) 
and for untreated versus the different treat-
ments in B (two experiments). Results are 
expressed as mean ± SEM. *, P < 0.05; **, P < 
0.005; ***, P < 0.0005.
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memory lymphocytes that contribute to the protective adap-
tive response. Many questions remain, however, as to the un-
derlying molecular mechanisms and the temporal window when 
the effector versus memory fate decision is made. In particu-
lar, the nature and timing of TCR signals specifically required 
for programming the memory fate of CD8+ T lymphocytes 
have remained elusive.
Evidence exists that signaling differences may determine 
the fate of naive CD8+ T lymphocytes upon activation (Lauvau 
et al., 2001; Badovinac et al., 2005; Daniels et al., 2006; Tewari 
et al., 2006; Chang et al., 2007; Teixeiro et al., 2009). Several 
such fate-determining molecules regulating memory but dis-
pensable for effector CD8+ T lymphocyte differentiation have 
been identified, and most of them are distal or unrelated to 
TCR-triggered pathways. These include surface receptor BTLA 
(Krieg et al., 2007), intracellular signaling molecules such as 
TRAF-6 and the mTOR kinase (Araki et al., 2009; Pearce et al., 
2009), and transcriptional regulators such as Bcl-6, Eomes, 
MBD2, Id2, and TCF-1 (Ichii et al., 2002; Intlekofer et al., 
2005; Cannarile et al., 2006; Kersh, 2006; Zhou et al., 2010).
In the present work, we report that naive N-ras/ antigen-
responding CD8+ T lymphocytes were able to efficiently expand 
and differentiate into cytolytic effectors but not into memory 
cells with protective function. As previously shown for CD4+ 
T cells (Iborra et al., 2011), CD8+ T cells from N-ras–deficient 
mice exhibited reduced sensitivity to antigen. However, this was 
seemingly without effect on antigen-mediated primary T cell 
CD8+ T cells could be detected among PEC, and there was 
no difference in percentage between wild-type and N-ras/ 
cells or between those transduced with control and with Eomes-
expressing retroviruses (Fig. 10 A, top). After a secondary 
challenge with rVACV-OVA (Fig. 10 A, bottom), both trans-
duced and nontransduced transferred wild-type OT-I cells ex-
panded, as anticipated, and Eomes overexpression only conferred 
a minor benefit (Fig. 10 B, left). As also expected, N-ras/ 
OT-I CD8+ cells were not able to expand, whether untrans-
duced or transduced with MigR1 control retrovirus. In sharp 
contrast, forced expression of Eomes in these antigen-specific 
N-ras/ cells allowed a highly significant secondary expan-
sion in response to virus infection (Fig. 10, A and B, bottom). 
Similar results were obtained when responding cells in the spleen 
were analyzed. Again, forced expression of Eomes in N-ras/ 
CD8+ T cells allowed their otherwise defective secondary ex-
pansion in response to viral infection, with the proportional 
improvement being superior in N-ras/ cells to that in WT 
counterparts during the secondary but not the primary re-
sponse (Fig. 10 B, right). Collectively, this data strongly sup-
ports a role for N-ras in coupling antigen receptor signaling 
to regulation of Eomes expression and to memory program-
ming in CD8+ T lymphocytes.
DISCUSSION
During viral infections, antigen-specific naive CD8+ T lym-
phocytes give rise to both short-lived effectors and long-lived 
Figure 9. Late involvement of mTOR in 
the induction of Eomes after antigen 
stimulation. Purified N-ras+/+ and N-ras/ 
OT-I CD8+ T lymphocytes were stimulated in 
vitro as in Figs. 7 D and 8 and treated or not 
with rapamycin in the absence (A) or in the 
presence (B) of IL-12. At the indicated times, 
cultures were stained for CD45.1 and CD25 
for gating and for transcription factors  
T-bet and Eomes and analyzed by FACS (three 
experiments for both A and B). Results are 
expressed as mean ± SEM. Statistical signifi-
cance is indicated for untreated WT versus  
N-ras/ cells (top asterisks) and for rapa-
mycin treated versus untreated N-ras/ cells 
(bottom asterisks). **, P < 0.005; ***, P < 0.0005.
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antiviral function. This is consistent with previous work em-
phasizing the role of quality of memory T lymphocytes for 
efficient protective immunity (Lauvau et al., 2001). N-ras would 
thus partake in a CD8+ T lymphocyte memory differentia-
tion program as a TCR-proximal and specific transducer of 
early signals.
The balance of expression of transcription factors Eomes 
and T-bet has been reported to influence whether CD8+  
expansion and acquisition of effector functions, either in vitro 
or in vivo. This is in agreement with previous reports (Zehn 
et al., 2009; Leignadier and Labrecque, 2010) and supports 
the existence of compensatory mechanisms enhancing anti-
gen sensitivity in antigen-experienced T cells (Kumar et al., 
2011). N-ras deficiency impinged instead on both the quan-
tity and functional quality of memory cells, but more promi-
nently on the latter, and severely compromised their protective 
Figure 10. Forced retroviral expression of Eomes in vivo restores CD8+ memory generation in the absence of N-ras. N-ras+/+ or N-ras/ OT-I 
CD45.1+/+ splenocytes were stimulated with OVA peptide in vitro for 24 h, CD8+ T cells purified, transduced with control GFP-expressing (MigR1), or with 
GFP-Eomes-expressing retroviruses and separately injected into naive CD45.1/ CD45.2+/+ N-ras+/+ recipient mice that were infected concurrently or 14 d 
later with rVACV-OVA. On day 8 after primary exposure to antigen, and on day 5 after secondary infection, CD8+ PEC and splenocytes were analyzed by 
flow cytometry, as indicated. Representative dot plots of PEC (A) as well as graphs representing four individual mice in each group (B) of retrovirus-trans-
duced (GFP+) and transferred (CD45.1+) CD8+ lymphocytes from PEC and spleen during the primary and secondary response, as indicated, are depicted.  
In A, numbers refer to percentage cells with respect to all CD8+ T lymphocytes, including GFP CD45.1 endogenous CD8+ T cells. In B, numbers represent 
the percentage of GFP+ transduced cells with respect to total CD45.1+ transferred CD8+ T cells, excluding endogenous CD8+ T cells; horizontal bars show 
the mean values. A representative experiment out of two is shown. ***, P < 0.0005.
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antigen. In vivo, rapamycin treatment also enhanced Eomes 
expression in WT and N-ras/ CD8+ T cells. However, Eomes 
expression in treated N-ras/ cells rarely reached the levels 
of treated WT cells. This resulted in the partial rescue by ra-
pamycin of each of the CD8+ T cell defects associated with 
N-ras deficiency in vivo. These concordant results may reflect 
a late downstream convergence of signaling pathways involv-
ing N-ras and mTOR at the level of Eomes, with N-ras and 
mTOR acting in opposite manners on Eomes expression. In 
this scenario, rapamycin treatment during priming would 
allow N-ras/ CD8+ T cells to reach a minimal threshold of 
Eomes expression for memory commitment. However, be-
cause of the earlier, mTOR-independent defect on Eomes 
induction impinged by the N-ras deficiency, the mTOR in-
hibitor would only partially rescue the memory defect of 
N-ras/ mice. Alternatively, N-ras could critically regulate, 
apart from Eomes, other memory fate-determining molecules 
in CD8+ T cells.
To date, only a handful of positive regulators of Eomes 
have been identified in CD8+ T cells, including Runx3 (Cruz-
Guilloty et al., 2009), Notch (Cho et al., 2009), and TCF-1 
(Zhou et al., 2010). Our study identified N-ras as a novel in-
ducer of Eomes expression, but in contrast to the aforemen-
tioned ones, N-ras was distinctively required for programming 
memory but not effector CD8+ T cell fates. Furthermore, 
among the positive regulators of Eomes, N-ras would be the 
most proximally linked to the TCR. Suppression of Eomes has 
recently been shown to enhance IL-17 expression and Th17 
differentiation (Ichiyama et al., 2011), which resembles the 
phenotype of TCR-activated CD4+ T lymphocytes in N-ras/ 
mice (Iborra et al., 2011; unpublished data). This further supports 
the notion that N-ras, but not the other Ras isoforms, specifi-
cally couples TCR signaling and induction of Eomes.
A recent study in a fluorescent Eomes reporter mouse (Paley 
et al., 2013) showed that expression of Eomes was very stable 
along the effector-to-memory CD8+ T cell differentiation after 
acute viral infection. Notably, in agreement with previous re-
ports (Intlekofer et al., 2005; Banerjee et al., 2010), Eomes was 
found to be equally expressed in memory precursors and ter-
minal effectors. However, Eomes expression correlated with 
improved central memory formation but not with enhanced 
primary effector response. Consistent with this, we found that 
retrovirally forced expression of Eomes in N-ras/ antigen-
specific CD8+ T cells rescued their defective secondary expan-
sion in response to viral infection while having no effect on their 
primary response. Collectively, these data support a direct, non-
redundant and specific role of N-ras in coupling antigen re-
ceptor signaling to early Eomes induction and thus to memory 
development in CD8+ T lymphocytes. Our data also further 
support Eomes as a marker to reliably identify the memory 
potential of CD8+ T cells early after their response to antigen.
Because N-ras was dispensable for the generation and func-
tion of primary effector cells, our findings collectively support 
the concept that the TCR recruits distinct signaling pathways 
for programming effector and memory fates. Furthermore, they 
suggest that isoform-specific Ras inhibitors could be of value 
T lymphocytes commit to memory or effector cells (Intlekofer 
et al., 2005). High T-bet expression seems to favor effectors 
(Matsuda et al., 2007; Yeo and Fearon, 2011), whereas per-
sistent Eomes expression is proposed to enhance memory lym-
phocyte differentiation (Joshi et al., 2007; Rao et al., 2010). 
This has been determined in response to IL-2 (Pipkin et al., 
2010) or in contexts with designed antigen-presenting cells 
and with cytokines providing inflammatory (IL-12) or survival 
(IL-7 and IL-15) signals that may predominate over and po-
tentially obscure early TCR signals (Intlekofer et al., 2005; 
Rao et al., 2010). When we focused on early antigen-mediated 
activation of naive CD8+ T cells in our in vitro system with-
out added cytokines or costimulatory signals, we found that 
TCR-mediated induction of T-bet was independent of N-ras. 
Of interest, unlike antigen-exposed CD8+ T cells, activated 
CD4+ T lymphocytes required N-ras for T-bet induction 
and IFN- production (Iborra et al., 2011), suggesting that 
N-ras could be differentially required for TCR-elicited func-
tions in CD4+ and CD8+ T cell lineages or depend on other 
concurrent signals.
With regard to Eomes, TCR-mediated signals inducing its 
expression and their relevance to effector versus memory fate 
choice had remained unclear. TCR engagement results in ac-
tivation of the PI3K–AKT and ERK pathways downstream 
of active Ras (Smith-Garvin et al., 2009), although which Ras 
isoforms are specifically involved was unknown (Mor and 
Philips, 2006). We now report that antigen-responding CD8+ 
T cells lacking N-ras have a major defect in Eomes induction 
in vitro and in vivo. A similar defect is revealed when PI3K, 
particularly PI3K, and AKT are pharmacologically inhibited 
in WT cells in vitro. Because antigen-stimulated N-ras/ 
CD8+ T cells also showed an intrinsic impairment in sustaining 
PI3K–AKT activation, our data suggest that N-ras, through 
PI3K–AKT, mediates TCR signals required for up-regulation 
of Eomes, and thus for concomitant programming of the mem-
ory phenotype. Nonetheless, the involvement of other PI3K 
family members (Delgado et al., 2009) in Eomes regulation 
cannot be presently excluded. In contrast, in antigen-responding 
CD8+ T cells, we observed that N-ras deficiency had no major 
effect on ERK activation, suggesting that the ERK pathway 
is dispensable for Eomes induction. Thus, N-ras would clearly 
stand out among other Ras isoforms, having much less im-
pact on ERK than on the PI3K–AKT pathway, and thereby 
dominating the induction of Eomes and of memory in TCR-
activated CD8+ T cells.
A critical role for mTOR in determining whether CD8+ 
T lymphocytes adopt an effector versus memory cell fate was 
identified using the mTORC1 inhibitor rapamycin (Araki et al., 
2009; Pearce et al., 2009). Furthermore, rapamycin has been 
reported to inversely affect Eomes and T-bet levels in CD8+ 
T cells following antigen stimulation in the presence of IL-12, 
with the inhibitor favoring the persistence of Eomes over T-bet 
(Rao et al., 2010; Li et al., 2011). We found that rapamycin 
promoted Eomes expression in vitro while leaving T-bet un-
affected, in both WT and N-ras/ CD8+ T cells, but impor-
tantly, this happened only at late time points after exposure to 
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for specific control of pathogenic memory T lymphocytes, or 
alternatively as anti-cancer therapeutics without detrimental 
side effects on patients’ immunity.
MATERIALS AND METHODS
Mice and peptides. N-ras+/+ mice (C57BL/6 strain) were purchased from 
Charles River. N-ras/ mice (H-2b haplotype; Umanoff et al., 1995) were 
bred with C57BL/6 for six generations and subsequently crossed with OT-I 
TCR transgenic mice to generate OT-I TCR transgenic N-ras/ mice. All 
animal studies were approved by CSIC and Instituto de Salud Carlos III’s 
Review Boards and were performed in accordance with national regulations.
Peptides 257SIINFEKL264 from OVA and 20TSYKFESV27 (B8R) from 
VACV soluble IFN-R homologue (Moutaftsi et al., 2006) were synthe-
sized in an Applera peptide synthesizer model 433A, purified, and deter-
mined to be homogeneous by HPLC analysis. OVA variant peptides Q4R7 
(SIIQFERL) and Q4H7 (SIIQFEHL) were a gift of H. Van Santen (Centro 
de Biología Molecular Severo Ochoa, Madrid, Spain).
MHC peptide pentamers and antibodies. The Pro5 MHC class I H-2K 
OVA and H-2KbB8R pentamers and FITC–anti-CD8 and anti-CD19 were 
obtained from ProImmune. PE–anti-CD8, PE–anti-CD69, APC–anti-CD25, 
PE–anti-CD44, APC–anti-CD62L, PE–anti-IL-2, PE–anti–IFN-, biotinyl-
ated anti-CD45.1, APC–anti-CD45.1, PerCP-Cy5.5–anti-CD45.2, PE–anti-
AKT phosphorylated at Thr 308, and PE–anti-ERK1/2 (pT202/pY204) were 
all anti–murine proteins antibodies (BD). PE–anti–mouse Eomes and PerCP-
Cy5.5–anti–mouse/human T-bet were obtained from eBioscience. Antibody 
to mTOR phosphorylated at Ser 2481 was from Cell Signaling Technology.
Flow cytometry and intracellular staining of cytokines, phosphorylated 
proteins, and transcription factors. Intracellular staining for IL-2 after pri-
mary activation of OT-I CD8+ T lymphocytes was performed after a 3-h stimu-
lation with peptide-pulsed DCs. The co-cultures were then incubated overnight 
in the presence of brefeldin A before staining for FACS according to conven-
tional procedures. In the ex vivo assays, cells were stimulated with an excess of 
peptide (1 µM) for up to 2 h and stimulated for a further 4 h in the presence of 
brefeldin A. Cells were then stained with FITC–anti-CD8, fixed, and incubated 
with PE–anti–IFN- during permeabilization (Dako; Johnstone et al., 2004).
The intracellular staining for phosphorylated ERK, AKT, and mTOR, 
was performed as previously described (Krutzik and Nolan, 2003). In brief, 
after surface staining, the cells were fixed with formaldehyde, permeabilized 
with methanol, and stained with phosphospecific antibodies. The intracellu-
lar staining of T-bet and Eomes was performed using the Foxp3 fixation/
permeabilization buffer (eBioscience), according to the protocol recom-
mended for detecting nuclear antigens.
Events were acquired using a FACSCanto flow cytometer and the data were 
analyzed using FACSDiva software (BD). Representative dot plots or histograms 
of an individual mouse per group are shown in the figures. Percentage of stained 
cells was calculated and is indicated within dot plots. Percentage and mean fluor-
escence intensity (MFI) data from sets of experiments are graphed as the 
mean ± SEM. An average of 10,000 CD8+ cells was analyzed in each sample. 
Background activation obtained with nonpulsed cells (0–0.3%) was subtracted.
BM–derived DCs. DCs were generated from BM progenitors. Freshly pre-
pared BM cells were cultured in the presence of 200 U/ml GM-CSF (Pepro-
Tech) and fed with GM-CSF on days 3 and 6. After 7 d, nonadherent cells 
with a typical DC morphology and a myeloid DC phenotype (MHC class 
II+, CD11c+, and CD8) were collected (Medina et al., 2009). Maturation 
of DCs was performed by the addition of 0.5 µg/ml LPS to cultures on day 7. 
Mature DCs (mDCs) showed a mature morphology and up-regulated CD40 
and CD86 costimulatory molecules and were collected 1 h later for immu-
nizations or 16 h later for other purposes.
In vitro stimulation of OT-I CD8+ T lymphocytes. CD8+ T lympho-
cytes were isolated from the spleens of OT-I TCR transgenic N-ras+/+ and 
N-ras/ mice by negative selection using Miltenyi magnetic beads. 1 × 106 
CD8+ T cells were stimulated with either 5 × 106 WT DCs pulsed with 
titrated concentrations of OVA or agonist peptides or with 6 × 106 CD45.1 
CD45.2+ WT splenocytes pulsed with 109 M OVA peptide. For some ex-
periments, 2 ng/ml IL-12 (R&D Systems) was added to the cultures. When 
indicated, cells were pretreated 20 min before stimulation and kept thereafter 
with 20 nM PI3K inhibitor wortmannin (Sigma-Aldrich), 50 µM ERK kinase 
(MEK) inhibitor PD98059 (EMD Millipore), 10, 5, and 2.5 µM ERK kinase 
(MEK) inhibitor UO126 (Cell Signaling Technology), 10, 5, and 2.5 µM 
PI3K inhibitor LY294002 (Cell Signaling Technology), 250, 125, and 62.5 nM 
PI3K inhibitor VII (EMD Millipore), 1, 0.5, and 0.25 µM M PI3K in-
hibitor VI (EMD Millipore), 10, 5, and 2.5 µM PI3K inhibitor (EMD Mil-
lipore), 1, 0.5, and 0.25 µM AKT inhibitor VIII (EMD Millipore), or 2.2 nM 
mTORC1 inhibitor rapamycin (Sigma-Aldrich).
Proliferation was assessed by labeling OT-I CD8+ T lymphocytes with 
5 µM CFSE (Molecular Probes) and coculturing them with mDC prepulsed 
with 107 M OVA peptide. CFSE dilution was analyzed 72 h later.
CTL lines were generated by culturing purified OT-I CD8+ cells with 
109 M SIINFEKL-pulsed DCs for 72 h at an E/T ratio of 5/1 before add-
ing human rIL-2 (NCI Preclinical Repository). The CTL lines were then used 
2 d later for in vitro 51Cr-release cytotoxicity assays at an E/T ratio of 5/1 
(Samino et al., 2004).
Viral infection, cytotoxicity assay, DC immunization, and rapamycin 
treatment in vivo. VACV strain WR and the recombinant virus encoding 
full-length OVA (rVACV-OVA) based on the WR strain were provided by 
J.W. Yewdell and J. Bennink (National Institutes of Health, Bethesda, MD). 
Stocks were grown in CV-1 monolayers and consisted of clarified sonicated 
cell extracts.
Mice were infected either i.p. with 106 PFU of rVACV-OVA or intra-
dermally in the ears with 5 × 104 PFU of VACV WR (Tscharke and Smith, 
1999). In this case, the evolution of the infection was monitored by measur-
ing the diameter of the ear lesion with a digital caliper. For DC immuniza-
tions, mice were inoculated i.p. with a mixture of 5 × 105 mDCs pulsed 
with 1 µM B8R peptide and 5 × 105 mDCs pulsed with 1 µM OVA peptide, 
or with mDCs pulsed with only one of the peptides.
For virus titration ex vivo, the ventral and dorsal dermal sheets of infected 
mouse ears were separated using forceps and incubated with 50 µg/ml liberase CI 
(Sigma-Aldrich) for 1 h at 37°C to prepare ear homogenates. After five freeze-
thaw cycles, ear and mechanically prepared ovary homogenates were serially di-
luted, inoculated onto CV-1 cells, and stained 24 h later with crystal violet. Each 
dot in the figures represents the virus titer in each ear or ovary from individual 
mice and the thick horizontal bars represent the mean values for each group.
Rapamycin (Sigma-Aldrich) was administered in 5% Tween 80 and 5% 
polyethylene glycol 400 (Sigma-Aldrich) in saline solution (Dehay et al., 
2010). Rapamycin or vehicle was inoculated i.p. daily at a low dose (75 mg/kg 
per mouse; Araki et al., 2009) 1 d before immunization or infection and for 
an additional 7 d during the T lymphocyte expansion phase.
In vivo cytotoxicity assays with N-ras+/+ and N-ras/ splenocytes were 
performed as previously described (Medina et al., 2009). N-ras+/+ and N-ras/ 
splenocytes were each split in two populations, labeled with either a high or a 
low concentration of CFSE, and washed. N-ras+/+ and N-ras/ CFSEhi cells 
were pulsed with OVA peptide, mixed with unpulsed CFSElo cells, their 
actual relative ratio in the mixture measured by cytometry, and injected i.p. into 
infected, immunized, or control syngeneic recipients. The peritoneal cavity 
was lavaged 16 h later. The cells were then analyzed by FACS to measure 
in vivo killing. Specific lysis was calculated using to the formula: [1  (ratio 
unprimed/ratio primed) × 100], where the ratio unprimed is %CFSElo/
%CFSEhi cells remaining in the control recipients and the ratio primed is 
%CFSElo/%CFSEhi cells remaining in the experimental recipients. Represen-
tative histograms of an individual mouse per group are shown in the figures. 
The numbers in the histograms indicate the percentage of specific lysis. Mean 
specific lysis data from sets of experiments are graphed as the mean ± SEM.
Adoptive transfer and evaluation of in vivo responses. Around 200 
CD8+ purified OT-I T cells from N-ras+/+ mice (CD45.1+ CD45.2+) and/or 
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from N-ras/ mice (CD45.1+ CD45.2) were mixed, their actual relative ratio 
in the mixture measured by cytometry, and adoptively transferred i.v. into the 
same intact congenic N-ras+/+ recipients (CD45.1 CD45.2+). In secondary re-
sponse experiments, OT-I cells were first transferred into separate CD45.1 
CD45.2+ recipients that were then immunized with mDCs pulsed with OVA 
peptide. Transgenic OT-I cells were purified ex vivo 8 d after priming in two 
steps. CD8+ T cells were first negatively selected and then enriched in CD45.1+ 
OT-I cells by positive selection using magnetic beads (Miltenyi Biotec). Equal 
numbers of primed N-ras+/+ and N-ras/ OT-I cells (200) were then co-
transferred into the same congenic N-ras+/+ recipients that were subsequently 
infected with rVACV-OVA. The number of splenic N-ras+/+ and N-ras/ 
transgenic OT-I cells was determined 5 d after challenge. For some experi-
ments, OT-I cells and recipients were treated with rapamycin. The number of 
CD45.1+ OT-I cells was determined after staining and FACS evaluation. The 
total number of adoptively transferred N-ras+/+ and N-ras/ cells was calcu-
lated by multiplying the total cell count by the fraction of CD8+ CD45.1+ 
CD45.2+ or CD8+ CD45.1+ CD45.2 cell gates, respectively.
Retroviral transduction. Retroviral vector MigR1 expressing GFP and 
bicistronic retrovirus expressing GFP and Eomes were obtained from S. Reiner 
(Columbia University Medical Center, New York, NY; Intlekofer et al., 2005). 
Retroviruses were packaged by transient transfection of 293T cells with the 
retroviral vector along with pCLeco and retroviral transduction of antigen-
specific CD8+ T cells was performed following a previously described proce-
dure (García-Peydró et al., 2003). In brief, splenocytes from CD45.1+ 
N-ras+/+ or N-ras/ OT-I TCR transgenic mice were incubated with 109 
M OVA peptide for 24 h, and CD8+ T cells were purified and then spin-
infected with control or Eomes-expressing retrovirus-containing superna-
tants in the presence of 8 µg/ml polybrene. The retrovirally infected cells 
were transferred into N-ras+/+ CD45.2+ recipients (105 cells/mouse), which 
were infected with 106 PFU rVACV-OVA. To study the primary response, 
PECs were analyzed 8 d after first exposure to antigen. Some recipients were 
infected 14 d later and the secondary response was similarly analyzed 5 d p.i.
Statistical analysis. Data are represented as means and SD or SEM. Statistical 
significance of differences between the means of experimental groups was 
determined using an unpaired two-tailed Student’s t test.
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